
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic ...
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1 …